Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
pivotal data from its global ARROS-1 Phase 1/2 clinical trial for zidesamtinib. The novel ROS1-selective inhibitor is being developed for TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer/NSCLC. The company also provided updates on the front-line development strategies for its parallel lead programs in both ROS1-positive and ALK-positive NSCLC. For zidesamtinib, Nuvalent has aligned with the FDA on its NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC. A physician standing in a lab, with vials of biopharmaceuticals in hand. The FDA has agreed to accept the NDA for participation in the Real-Time Oncology Review/RTOR pilot program, which allows for earlier submission of topline data to expedite the FDA's evaluation. Nuvalent plans to initiate a rolling NDA submission this July, with completion targeted for Q3 2025. Nuvalent Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical compa
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare ConferencePR Newswire
- Nuvalent (NASDAQ:NUVL) had its price target lowered by analysts at JPMorgan Chase & Co. from $147.00 to $145.00. They now have an "overweight" rating on the stock.MarketBeat
- Nuvalent (NASDAQ:NUVL) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
NUVL
Earnings
- 5/8/25 - Miss
NUVL
Sec Filings
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- 12/23/25 - Form 4
- NUVL's page on the SEC website